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Sarcomas are malignant tumors emerging from mesenchymal tissues including bone, 
cartilage, adipose tissue and muscle. Sarcomas are rare, accounting for only 2 to 3 percent of all adult 
cancers. Underlying pathogenic mechanisms are slowly beginning to be understood and in about a 
third of sarcomas include unique chromosomal translocations that generate fusion genes, which 
encode fusion proteins most of which function as aberrant transcription factors. However, two thirds 
of sarcoma harbor complex genetic alterations that preclude clear assessment of their pathogenesis. 
Numerous studies suggest that the immune system has an important role in the control of 
tumor progression. It is documented that patients with tumors having a strong cytotoxic T cell 
infiltrate have a better overall survival rate than those with tumors that do not. It is also well known 
that cancer can evade the host immune defenses. Thus it seems important to characterize tumor 
immune infiltrates and determine their precise role with regard to tumor growth. Unlike other types 
of cancer, immune infiltrates in sarcomas have been little studied. 
The aim of this study is to characterize the phenotype of immune cell populations infiltrating 
different types of sarcomas. Samples of seven types of sarcomas have been analyzed. Following 
tumor dissociation, immune infiltrates were analyzed by flow cytometry. Our preliminary results 
show myeloid cells to be the dominant population, followed by small amounts of T cells. The myeloid 
population is heterogeneous and is composed of different cell subsets, including macrophages 
(HLADR+CD11b+) and cells displaying HLADR- plus a combination of CD11b+ CD15+ and CD33+ 
phenotypes. These cells could correspond to myeloid-derived suppressor cells (MDSCs), which are 
strongly immunosuppressive and promote tumor growth and metastasis. Different T cell 
subpopulations have also been found. The dominant subset consists of CD4+ T cells, typically 
associated with helper functions. Samples with high levels of CD4+ T cells and CD25+Foxp3+ T cell 
(that correspond to regulatory cells) had low counts of CD4-/CD8+ T cells that are associated with 
cytotoxic functions. 
Immune cell infiltrates in sarcomas are poorly described in the literature. A better phenotypic 

























 Cancer is a genetic disease that affects people of any age, gender and race. According to the 
World Health Organization, cancer figures among the leading causes of death worldwide, accounting 
for 8.2 million deaths in 2012. Cancers are traditionally classified into multiple categories depending 
on the identity of the affected tissue (carcinomas, sarcomas, leukemias) and their histopathological 
characteristics (local invasiveness, mitosis, pleomorphic cell nuclei). However, they are now 
increasingly categorized according to the genetic mutations they bear and associated epigenetic 
modifications of the genome. Thus, our view of cancer is rapidly changing from a largely descriptive 
toward a much more functional classification based on rational parameters that underlie the 
mechanisms according to which they develop and progress. Cancer generally arises from a single cell. 
One or more mutations are needed in specific genes (proto-oncogenes, tumor suppressor genes, 
DNA repair genes) to transform a normal cell into a tumorigenic one. Although some genetic 
mutations are inherited, most cancers arise as a result of the accumulation of new mutations caused 
by environmental factors including, among others, UV light, radiation, infection, diet and chemicals 
(Wogan et al., 2004). Tumorigenesis is the process which may occur following transformation of a 
cell, depending on how the cell responds to transforming agents. Transformation that leads to 
tumorigenesis provides the cell with multiple new properties such as evading apoptosis, self-
sufficiency in growth signals, insensitivity to anti-growth signals, tissue invasion and metastasis, 
limitless replicative potential and sustained angiogenesis (Hanahan & Weinberg, 2000).  
 Sarcomas are malignant tumors emerging from mesenchymal tissues, including bone, 
cartilage, adipose tissue and muscle. Sarcomas are quite rare, accounting for only 2-3% of all adult 
cancers but up to 15% of pediatrics ones. Although new multidisciplinary therapeutic approaches are 
increasingly applied, the overall survival rate of five years remains strongly compromised if surgery is 
not curative. Gradually, underlying pathological mechanisms are beginning to be understood, chief 
among which are unique chromosomal translocations that give rise to fusion proteins, most of which 
appear to function as aberrant transcription factors or transcriptional regulators as illustrated in 
Ewing and synovial sarcoma (Riggi et al., 2007a; Riggi et al., 2007b; Suva et al., 2007). But for the vast 
majority of sarcomas (leiomyosarcoma, high-grade spindle cell sarcoma, myxofibrosarcoma, 
pleomorphic sarcoma, dedifferentiated liposarcoma and undifferentiated myxofibrosarcoma) 
underlying pathogenic mechanisms still remain unclear and classification remains primarily based on 
morphology. According to the French Fédération Nationale des Centres de Lutte Contre le Cancer 
(FNCLCC), the grade of a sarcoma is based on a score - including tumor differentiation, mitotic rate 
and amount of tumor necrosis. The grade is a sign of how likely the cancer will spread. For example 
low-grade sarcomas contain well-differentiated cells and tend to disseminate less. Higher-grade 













Figure 1. The primary tumor microenvironment (Joyce and Pollard, 2009) 
The microenvironment surrounding tumor cells is composed of diverse 
types of cells including hematopoietic cells such as macrophages, 
lymphocytes, myeloid-derived stem cells and a variety of stromal cells 
ranging from differentiated myofibroblasts to mesenchymal stem cells.  
 
 Cancer immune surveillance, elimination and escape are old concepts that are beginning to 
be better understood in light of in-depth molecular and cellular analyses. Cancer is intimately linked 
to inflammation (Coussens & Werb, 2002), where innate immunity can play the role of a double-
edged sword. Numerous studies suggest that adaptive immunity plays an important role as well in 
the control of tumor progression (de Visser et al., 2006). It is well known that patients with tumors 
that have abundant cytotoxic infiltrates have a better overall survival rate than do those with tumors 
that do not (Sorbye et al., 2011; Sorbye et al., 2012; Galon et al., 2006; Galon et al., 2013). 
Furthermore, new functional sub-populations of immune cells continue to be described (Prendergast 
& Jaffee, 2013) and contribute to a better understanding of the notion of immune surveillance of 
tumor behavior (Hanahan & Weinberg, 2011). 
Several types of immune cells are important in immune surveillance (Figure 1). Lymphocytes 
are divided in two major functional groups: B cells and T cells. B cells are the principal effectors in 
humoral immunity, being responsible for antibody production. T cells can be grouped into several 
subpopulations: according to phenotypic marker expression, i.e. CD4+, CD8+ and according to their 
more relevant functional properties. Thus, CD8+ cells have a predominantly cytotoxic role, killing 
cells by cell-to-cell interactions. CD4+ cells or T helpers are divided into several categories, including 
Th1, Th2 and Th17. Their role is to interact with other cells of the immune system to promote 
primarily cell-mediated (Th1) or humoral (Th2) immune responses. T regulatory cells (T regs), 
discovered during the '90s, are a subset of T helper cells (CD4+), which express CD25+ and 
transcription factor FoxP3. Their principal role is to inhibit proliferation and function of activated 
cytotoxic T cells (CD8+) and activated CD4+ T cells at least in part through a cell-to-cell contact 
dependent mechanism. The ratio CD4/CD8 is important for patient survival. It has been shown that 
cancer patients with a higher rate of CD8+ cells have a better overall survival than those who do not. 
In addition to “classical” immune populations of T cells that express only CD4 or CD8, new subsets of 
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T cells have been described in literature (Thompson et al., 2006). These new populations have a 
double negative (CD4-CD8-) or double positive (CD4+CD8+) phenotype. NK cells are a small subset of 
lymphocytes that act similarly to CD8+ T cells and display cytotoxic activity toward virally infected or 
tumor cells that express low levels of major histocompatibility complex molecules. Unlike T cells, NK 
cells do not possess specific receptors for tumor antigen recognition in the context of MHC (Moretta 
et al., 2014). 
 Another important family of immune cells frequently found at the tumor site are myeloid 
cells. Monocytes are blood precursors of macrophages. Macrophages are plastic cells, capable of 
differentiation into at least two distinct populations - M1 and M2 (Martinez & Gordon, 2014). M1 are 
generally tumor suppressive, producing effector molecules (reactive oxygen species), including 
cytokines that promote a pro-inflammatory Th1 response. M2 cells promote a Th2 response, which is 
anti-inflammatory and favors tissue repair and remodeling. This capability can be used by the tumor 
to model its microenvironment according to its needs. Macrophages can undergo conditioning by 
tumor cells to become tumor-associated macrophages (TAMs). TAMs display phenotype 
characteristic of M2 macrophages (secretion of IL-10 and TGF-β) and are unable to trigger Th1-
polarized immune response (production of argininase, Zea et al., 2005) but rather induce T regs. They 
are present in well-established cancer and contribute to direct the local immune system away from 
antitumor function. TAM-derived factors promote tumor cell proliferation and survival (Chanmee et 
al., 2014). 
 A more recently identified functional population of myeloid cells is composed of myeloid-
derived suppressor cells (MDSCs), which have strong immunosuppressive activity and are frequently 
associated with tumor progression (Gabrilovitch & Nagaraj, 2009). Multiple mechanisms of action 
have been suggested. These cells can protect against autoimmunity but, on the other hand, can also 
induce tumor promoting effects through modulating the immune functions of macrophages, NK cells, 
B cells, T cells. MDSCs originate in the bone marrow as CD11b+ hematopoietic precursor cells. MDSCs 
gene expression is very variable between tumors. Although many studies have been carried out, it is 
very difficult to identify a unique phenotype of markers. Moreover, mechanisms leading to 
accumulation of MDSCs in bone marrow and blood of patients are incompletely understood, as well 
as the direct correlation between MDSCs, chronic inflammation and immunosuppressive state. 
 Unlike carcinomas, the immune infiltrate in sarcomas has been little studied. In this work, 
with a selected panel of markers we analyzed the main immune cell populations infiltrating tumor in 




















Materials and methods 
Tumor samples and enzymatic dissociation 
Eight different tumor samples were included in this study: a leiomyosarcoma (HGS8), a high-
grade spindle cell sarcoma (HGS17), a myxofibrosarcoma (HGS18), a pleomorphic sarcoma (HGS19), a 
dedifferentiated liposarcoma (HGS21), an undifferentiated myxofibrosarcoma (HGS23), a Wilms 
tumor, even though it is not a sarcoma, and a synovial sarcoma. Approval was obtained form the 
Ethics Committee of the Canton de Vaud, protocol number 260/15. To obtain a bulk of single cells, 
fresh samples were put in Petri dishes containing IMDM medium (Gibco) supplemented with 1% of 
penicillin/streptomycin (PS) antibiotics (Gibco) and mechanically dissociated using a scalpel. Samples 
were incubated at 37°C for two hours with collagenase type II and IV (0.5 mg/ml, Sigma) and DNase I 
(100 ng/ml, Roche). To obtain a single cell suspension, dissociated samples were passed through a 70 
m cell strainer. Single-cell bulk samples (tumorigenic cells, immune infiltrate and dead cells) were 
then frozen and stored in liquid nitrogen. Each sample contained an average of 107 cells that were 
used for FACS staining. 
Antibody staining and data acquisition 
 Stainings have been performed on frozen samples after thawing. Samples underwent 
multiple washes in IMDM + 1% PS medium followed by resuspension in MACS buffer (PBS 1x-0.5% 
BSA-EDTA 2mM). To block all unspecific Fc-gamma receptors thus reducing unspecific fluorescence, 
cells were incubated 20 minutes at 4°C with FcR blocking reagent (human, Myltenyi). Then, they 
were washed and stained for 30 minutes (4°C) with specific antibodies in a total volume of 30 l on a 
96 V-well-plate. 7AAD and DAPI were used as markers of cell viability. 
 
Molecules Fluorochrome Dilution Purchase from 
CD33 eFluor450 1:20 eBioscience 
CD11b APC-eFLuor780 1:20 eBioscience 
CD8 Pacific Orange 1:25 exBio 
CD16 PerCP-Cy5.5 1:20 BD Pharmingen 
CD3 PC7 1:20 Beckman Coulter 
CD19 FITC 1:40 eBioscience 
CD15 PE 1:20 Beckman Coulter 
CD56 ECD 1:40 Beckman Coulter 
CD45 Alexa700 1:20 BD Pharmingen 
HLADR APC 1:20 BD Pharmingen 
CD4 PE 1:40 BD Pharmingen 
FoxP3 FITC 1:1 eBioscience 
CD25 APC 1:100 eBioscience 
7AAD ECD NA eBioscience 
DAPI NA 1:10000 NA 
Table 1. List of antibodies and working dilutions 
 
Four different antibody mixes were used to stain the samples (Joyce & Pollard, 2009). Table 1 
shows the list of antibodies, corresponding dilutions previously established in the laboratory and 
associated fluorochromes. The different antibody combinations are reported in figure 2. Around 106 
cells per condition were incubated. Mix 1 (CD19, CD14, CD56, CD16, CD3, HLADR, and CD45) was 
used to characterize the proportions of T cells, NK cells, B cells and macrophages. Mix 2 (CD15, CD3, 
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HLADR, CD45, CD11b and CD33) was used to characterize myeloid cells (Mirza et al., 2006). T cell 
subpopulations were analyzed using Mix 3 (CD4, CD56, CD3, CD45 and CD8) and Mix 4 (FoxP3, CD4, 
CD3, CD25and CD45). For Mix 4, containing antibodies targeting the FoxP3 nuclear protein, cells were 
permeabilized using the FoxP3 kit following manufacturer instructions (eBioscience, Anti-Human 
FoxP3, FITC staining set). A condition without FoxP3 antibody was used as control. Cells stained with 
anti-CD45 and live/dead markers were used as negative controls (Figure 2).  
 After incubation, cells were washed, resuspended in 100 µl of MACS buffer and transferred in 
a tube containing 400 µl of MACS buffer. Cells were kept protected from light and stored at 4°C until 
FACS acquisition. Stained samples were acquired on a Gallios Flow Cytometer (Beckman Coulter) and 
FlowJo V10 software was used for analysis. 
Before data acquisition, voltages were set up using unstained cells. A minimum of 4000 
living/single cells was acquired for each sample. To set up compensations, single positive stained 
beads (BD Comp-Bead Anti-Mouse Ig, k, BD Biosciences) were used to correct for fluorochrome 
spectral overlap. Compensations were calculated using FlowJo software. 
 
 
Figure 2. Antibody staining plan 
The first line on the top depicts the filters and the corresponding wavelengths that were used in the 
Gallios Flow Cytometer. The second line indicates to which fluorochrome each antibody of the same 
column is conjugated. Following lines correspond to the nine antibody mixes used in staining 
reactions. The first column on the left represents the name of each condition. Green cell correspond 




 HGS18 sample was chosen as a representative sample to show all gating strategies (Figures 3, 
4, 5 and 6). 
For all antibody combinations a common procedure was used to gate on the appropriate cell 
size and discard doublets and dead cells. Cells negative for 7AAD and DAPI stainings were considered 
as “living cells”. Immune cells were distinguished from tumor cells by their positive CD45 expression. 
These first four gating steps, “size”, “single cells”, “living cells” and “CD45+”, are critical to limit the 
non-specific fluorescence in later analysis, especially while targeting CD11b+ cell populations 
(Kuonen et al., 2010) (Figures 3, 4, 5 and 6). 
Specific gating strategies based on cell surface phenotype were then used for the analysis of 
the different immune cell proportions for each antibody mix. In figure 3, cells expressing CD3 marker 
among CD45+ cells were considered as T cells and included on “Ly T” gate. Figure 3 also depicts the 
gating strategy for B cells (red arrows), NK cells (green arrows) and CD14+ population (blue arrows). 
In the red pathway, the first gate P1, built over CD3- population, targets subpopulations expressing 
CD19+, a B cell marker. On P1 population, P2 gate discards cells expressing whether CD16 or CD14, 
which are markers of monocytes, NK cells and macrophages. “Ly B” selects cells with a CD19+CD56- 
phenotype. The green pathway represents the gating strategy for NK cells. P3 is the second gate 
build over CD3- population. It eliminates antigen-presenting cells selecting only cells negative for 
HLADR expression. NK cells were then considered as CD56+CD16+/- cells. In the blue pathway on the 
right, CD14+ cells were selected after discarding CD16-/CD14-CD56+ cells by gate P4, and looking at 
the positive expression of HLADR markers on CD14+ cells. Figure 4 shows the characterization of 
CD11b+HLADR+ macrophages and the characterization of different subsets of myeloid populations: 
HLADR-CD11b+/-, CD15+/-, and CD33+/-. The second mix of antibodies was used. Once the CD3- 
population was obtained, the first gate was built by targeting CD11b+HLADR+ over CD3- population 
(blue pathway). On the right side of the figure (green pathway), first, HLADR+ and then CD11b-CD33- 
cells were discarded (“HLADR-“, “CD11bCD33” gates). The expression of CD15 and CD33 markers was 
then evaluated on CD11b+CD33+/- cells. CD4+, CD8+, CD4-CD8- and CD4+CD8+ T cell subsets were 
analyzed on CD3+ population using the gating strategy depicted in Figure 5. Proportions of 





Figure 3. Gating strategy for the analysis of B, NK and CD14+ cells  
Headers at the top of dot plots indicate from which populations 
cells were gated. Red, green and blue arrows represent 






Figure 4. Myeloid cell characterization: gating strategy 
Headers at the top of dot plots indicate from which populations cells were gated. Blue and 
green arrows represent respectively gating strategies of macrophages and myeloid 
subpopulations. Histograms at the bottom show the expression of CD11b, CD33 and CD15 on 
























Figure 5. Gating strategy for the characterization of T cell subpopulation 
Headers at the top of dot plots indicate from which population cells were gated. CD4+ and 




Figure 6. Gating strategy for the characterization of T reg cell proportions 





Eight primary tumor samples were analyzed: high-grade spindle cell sarcoma (HGS17), 
myxofibrosarcoma (HGS18), pleomorphic sarcoma (HGS19), dedifferentiated liposarcoma (HGS21), 
undifferentiated/myxofibrosarcoma (HGS23), leiomyosarcoma (HGS8), Wilms tumor and synovial 
sarcoma.  
Wilms tumor is the most common childhood malignancy. Its pathogenesis lies within the 
mutation of a tumor suppressor gene (WT1). This gene encodes a transcription factor implicated in 
normal kidney and gonadal development. With current therapies, overall survival is around 80-90% 
(Davidoff, 2012). 
Because of the heterogeneity of the samples, Wilms tumor will be compared to the average 
of the high-grade spindle cell sarcoma group (HGS), while the synovial sarcoma will be presented 
separately. Indeed, for this last sample the CD45 staining was not able to discriminate between 
immune and tumor cells, most likely because of non-specific fluorescence or aberrant expression by 
tumor cells. 
Numbers of living cells were heterogeneous among samples, varying from 33% of single cells 
(1.7x104 cells) in HGS17 sample to 83% (9x104 cells) in HGS 21 sample (Figure 7). Compared to the 
mean value in the high-grade sarcoma group (64%), Wilms tumor displayed a lower amount of living 
cells representing 40% of the single cell population (4x104 cells).  
 
 
Figure 7. Percentages of living cell population in bulk samples 
As discussed previously, CD45, a general marker of immune cells, was used to discriminate 
immune cells from other cell types, such as endothelial or tumor cells. Figure 8 shows the proportion 
of immune infiltrates among cell bulk in all samples. Immune cell infiltrates were heterogeneous. 
With the exception of Wilms tumor sample for which the immune infiltrate represented 30%, 
immune cell infiltrates were generally abundant and ranged between 43% and 83% of living cells 






Figure 8. Percentages of total immune cells infiltrating sarcoma 
CD3 antigen was used to further characterize T cells among immune infiltrates, whereas B 
cells, CD14+ cells, other myeloid cells and NK cells were analyzed within the CD3- population. In high-
grade sarcoma samples, CD3- population was abundant and ranged between 55.3 and 98.3% of 
CD45+ immune cells. The proportion of CD3- cells was significantly lower in the Wilms tumor sample 
(around 10%, Figure 9).  
B cell infiltrates were rare. HGS17 and HGS8 tumors showed higher proportions compared to 
the average of other samples (0.14%), respectively 0.3% and 0.4%. The Wilms tumor displayed a 
similar B cell percentage as HGS18, HGS19, HGS21 and HGS23 tumors (Figure 10A). NK cells showed a 
similar distribution, with HGS17 and HGS8 tumors harboring higher proportions than other samples 
(Figure 10B). Regarding CD14+ cells, proportions were generally low (average of 6.28%), except for 
HGS18 (38%). Wilms tumor was comparable to other samples with a CD14+ cell component of 0.9% 
(Figure 10C). Compared to other populations, T cell proportions were higher but nevertheless 
heterogeneous, with an average of 5.4%. Wilms tumor was characterized by a 10% T cell content 
(Figure 10D). 
Assessment of Wilms tumor results in more detail revealed that adding percentages of CD3+ 
cells and CD3- cells did not reach 100%. These results could be explained either by experimental 
errors (e.g. suboptimal staining) or by the fact that our gating procedure was not sufficiently 
























Figure 10. Percentages of B cells (A), NK cells (B), CD14+ cells (C) and T cells (D) among CD45+ cells 
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Myeloid cell characterization 
Myeloid cells were analyzed among the CD3- population using the antibody combination Mix 
2 (Figures 2 and 4). Two major phenotypes were characterized: HLADR- cells and CD11b+HLADR+ 
cells, which correspond to a macrophage-like phenotype. HGS18 and HGS19 samples displayed the 
highest proportion of macrophages, 58.8% and 63.6%, respectively. In Wilms tumor, the percentage 
of macrophages was 37.1%, which is slightly inferior to the average of sarcomas (45.5%). 
Regarding HLADR- cells, results were heterogeneous ranging from 15.6% in HGS18 to 63% in 
HGS17. The average of all samples was slightly more than 30%. Wilms tumor showed a smaller 
proportion of HLADR- cells than the average of sarcoma samples (24%)(Figure 11). 
 
 
Figure 11. Percentages of HLADR- and HLADR+ myeloid cells populations 
We analyzed the expression of CD11b, CD15 and CD33 markers among HLADR- cells. These 
markers have been reported to be associated with MDSCs phenotypes. The vast majority of HLADR-
cells expressed CD11b (range 89.3-97.8%, average being 93.3 %)(Figure 12). Compared to sarcomas, 
Wilms tumor showed a lower proportion of HLADR-CD11b+ cells (64.1%). We then looked at CD33 
and CD15 expression among HLADR-CD11b+ populations (Figure 13). Three patterns emerge from 
these results. The largest population in HGS17, HGS21, HGS23 and HGS8 samples were cells 
expressing only CD11b (CD33-CD15)(purple bars). In these samples a smaller proportion of CD33-
CD15+ cells was also present (blue bars). The second pattern corresponds to HGS 18 and HGS 19 
samples for which proportions of CD33-CD15+ and CD33-CD15- were comparable and both close to 
50%. Wilms tumor showed a third pattern different from sarcoma samples. The largest populations 
were characterized by CD33+CD15- cells (green bar, 41%) and CD33-CD15- cells (39%). CD33-CD15+ 
cells represented almost 15% of HLADR-CD11b+ cells and a non-negligible population of double 










Figure 13. Distribution of cells according to the expression of CD33 and CD15 among HLADR-
CD11b+ cells 
T cell characterization 
 Figure 14 represents populations of cells expressing CD4 and CD8 and gives a general 
overview of T cell characterization. With the exception of HGS17, for which CD4+ proportion was 
dominant, other samples showed similar proportions of CD4+ and CD8+ T cells. However, 
proportions of CD4+ added to those of CD8+ correspond to more than 100% (especially for HGS18 
and HGS19), suggesting the presence of double positive cells. Double positive populations will be 





Figure 14. General proportions of CD4+ and CD8+ T cells 
It is important to highlight the observation that HGS17 displayed a unique pattern, with the 
absence of CD8+ and double positive cells. Wilms tumor displayed a similar phenotype compared to 
the average of CD4+ and CD8+ cell proportions in sarcoma samples, respectively 67% and 48%.  
Double negative lymphocytes (red bars) are dominant in HGS 17 and HGS 23, whereas double 
positive cells (purple bars) are high in HGS 19 and, to a lesser extent, in HGS 18. CD4+ single positive 
populations (green bars) are the largest in samples HGS18, HGS8 and Wilms tumor; whereas CD8 
single positive populations (blue bars) are present in all samples but totally absent in HSG17. There 
are more samples with a positive CD4:CD8 ratio (CD4 > CD8): HGS17, HGS18, HGS8 and Wilms tumor. 
Remaining samples (HGS19 and HGS 23) have a negative CD4:CD8 ratio (CD4 < CD8) or shown a high 
double positive population.  
 
 
Figure 15. Distribution of lymphocytes regarding the expression of CD4 and CD8 surface marker 
Proportions of T reg-like cells (CD4+CD25+FoxP3+) were also analyzed among CD3+ cells. 
Large proportions of T regs are present in HGS17 and in HGS18 samples (Figure 16). Proportions of T 
regs in HGS19 and HGS23 are lower and close to 5%. In other samples, T reg populations were 
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smaller. By comparing percentages of CD4+ cells to those of T reg (CD4+CD25+FoxP3+), T regs 
represented between 5% (HGS8) and 50% (HGS8). The hypothesis that T regs represented a major 




Figure 16. Proportion of T regs among CD3+ population 
Synovial sarcoma 
 Synovial sarcoma showed a different pattern concerning CD45 expression for which the 
proportion was higher than 90%. It is possible that tumor cells expressed CD45 making our analysis 
difficult. For this reason, we decided to show the analysis of this sample separately. 
 By comparing figure 17 with figure 3, populations in figure 17 were not clearly distinguishable 
and discrimination between negative and positive populations was impossible. These results strongly 
suggest that the tumor may express CD45. Moreover, it is possible that the tumor also expressed 
CD56 and possibly HLADR (gates P1 and P3). Nevertheless, we tried to analyze immune cell 
subpopulations. No CD3+, NK cells, B cells or CD14+ cells were found (Figure 17). We only detected a 
small population of HLADR+CD11b+ (around 15%) as well as CD11b+CD33+ cells (approximately 33 
















Figure 17. Synovial sarcoma: characterization of B cells, NK cells and CD14+ cells 
Headers at the top of dot plots indicate from which populations cells were gated. Red, green and 







Figure 18. Myeloid cells characterization in synovial sarcoma 
Headers at the top of dot plots indicate from which population cells were gated. Blue and green 
pathways represent respectively gating strategies of macrophages and myeloid subpopulations. 
Histograms at the bottom show the expression of CD11b, CD33 and CD15 in HLADR- cells (red lines). 





Discussion and future perspectives 
 Through this study, we characterized immune infiltrates in different types of high-grade 
sarcomas and in a primary sample of Wilms tumor. Each sarcoma displayed a different pattern in 
terms of size and composition of immune infiltrate, but one common feature was that dominant 
populations in each sample were myeloid cells and T regs.  
Because of the different nature of the samples, we chose to discuss Wilms tumor separately 
and compared it to the average pattern of sarcoma samples.  Even if some results were comparable, 
Wilms tumor displayed a unique pattern. Its total immune infiltrate (CD45+ cells) as well as the 
proportion of CD3- cells was lower compared to the average of sarcomas (Figures 8 and 9, 
respectively). Moreover, it also displayed a different pattern of CD11b+HLADR- myeloid cells (Figures 
12 and 13). T cell infiltrate was higher compared to the average of sarcoma samples (Figure 10D) and 
mainly characterized by CD4+ cells. However, the proportion of T reg cells was low (Figures 14, 15 
and 16). 
 Myeloid cells are mainly composed of MDSC-like cells and macrophages. MDSCs have been 
described as immunosuppressive cells (such as interference with T cell function) (Solito et al., 2014) 
with heterogeneous phenotypes that vary among different types of cancer (Gabrilovitch & Nagaraj, 
2009). Certain markers were selected, based on available studies, which seemed recurrent and 
present in different tumors: renal cell carcinoma (HLADR-CD11b+CD15+) (Zea et al., 2005), head and 
neck squamous cell carcinoma (HLADR-CD33+)(Almand et al., 2001) and carcinomas in general 
(CD15+)(Schmielau et al., 2001). As seen in the results, it could be said that there is “a phenotype per 
sample” and it may reflect and underlie the heterogeneity and complexity of cancer biology (Smith et 
al., 2013; Young et al., 2001). Throughout this study we did not focus on the association between 
immune cell infiltrates and clinical stages of patients. It would be interesting to correlate immune 
infiltrates with clinical stage and immunohistochemistry markers on one hand and genetic patterns 
on the other, to clinical data as it has been done in some studies (Gentles et al., 2015). 
It is important to keep in mind that MDSC is a functional characterization and no functional 
tests have been performed yet. Moreover, MDSC function has been studied in carcinomas and little 
is known about MDSCs in sarcomas and even less in the sarcomas used in this study. Different sets of 
markers are probably needed to characterize MDSCs in more detail in sarcomas. From the general 
results of this study, there is an inverse correlation between T cell and CD3- cell counts (data not 
shown). This could possibly be explained by the ability of MDSCs to interfere with T cell functions. 
However, more experiments need to be conducted to prove or invalidate such hypotheses, but it is 
conceivable that these cells are MDSCs with an immunosuppressive profile. 
 Macrophages are the other important subset constituting CD3- populations. Macrophages 
have been characterized as CD14+ and HLADR+CD11b+ populations (Ruffell et al., 2012). TAMs are 
often found in large quantities in tumor microenvironments, promoting cancer growth and spread 
(Kumar et al., 2010). It has recently been shown (in mammary cancers) that macrophages have 
multiple roles in cancer. By secreting IL-10, macrophages affect the normal function of cytotoxic T 
cells. Moreover, M2 macrophages, induced by Th2 responses, have been shown to be pro-
metastatic. Research using mouse models has shown that suppressing triggers of macrophage 
differentiation could prevent metastatic states and increase T cytotoxic cell counts. These 
mechanisms are thought to act not only through secretion of IL-10 but also through mechanisms 
mediated by myeloid cells, which are not fully understood (Ruffell, personal communication, EPFL 
lecture 2014). According to the procedures and results of this study, it is not possible to conclude the 
specific polarization of macrophages towards M1, M2 or TAM. For this purpose, functional studies 
would be required. In future experiments, it would be interesting to use fresh samples and to 
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quantify the secretion of IL-10 and determine whether these mechanisms are also found in 
sarcomas. 
 Tumor infiltrating lymphocytes are considered to be an indication of the immune reaction of 
the host and an estimation of the overall expected survival. It is well known that the presence of 
numerous CD8+ cells is associated with better survival prospects (Weinberg, 2013; Sorbye SW et al., 
2011). In samples with large CD4+ cell counts; there are also large counts of FoxP3+CD25+ cells, 
known as T regs. Under normal conditions, T regs account for 5 to 10% of total CD3- cells and can be 
augmented in some tumors (Prendergast & Jaffee, 2013). Results found in this study are close to 
those found in existing literature. T regs are known to be immunosuppressive and tissue repair 
promoting, thus enhancing tumor proliferation (Danese & Rutella, 2007). Although recent studies 
have shown that T regs are not automatically associated with poor prognosis and tumor immune 
evasion, it is recognized that a high T reg count is associated with tumor progression (deLeeuw et al., 
2012). 
 Some other populations have been characterized in past years. Double negative (CD4-CD8-) 
and double positive (CD4+CD8+) T cells have been described in recent studies (D’Acquisto & 
Crompton, 2011; Thomson et al., 2006). Although their functions remain very controversial, it seems 
that these populations could have an immunosuppressive role (Hillhouse & Lesage, 2013; Young et 
al., 2003). 
 Results of synovial sarcoma were difficult to analyze because of the diffuse expression of 
CD45 marker - either the immune infiltrate was dominant or the tumor also expressed this marker. 
According to the results of this study and the difficulties to better characterize immune cell 
subpopulations, it seems likely that the tumor is expressing CD45. This condition, although extremely 
rare, has been reported in literature under some circumstances of undifferentiated tumor or 
metastasis (Danbara et al., 2009). Other investigations (real time PCR and other FACS analysis) will be 
performed on this sample. One hypothesis might be that this mechanism of CD45 overexpression is 
implicated in tumor immune evasion, which may contribute to the poor prognosis of synovial 
sarcoma (Kerouanton et al., 2014). 
Results published early this year underline the importance of translational research and 
bringing discoveries from bench to bedside. By blocking CSF-1 (which is an activating trigger of 
macrophages) it has been shown that the tumor bulk was reduced in size and that more T cytotoxic 
cells were recruited to the tumor site (Ruffell, personal communication, EPFL lecture 2014). This is an 
example of how targeting specific populations or cytokines could provide potential future 
therapeutic options. 
For this study we used thawed primary samples that had been frozen after tumor 
dissociation. Analyses on this kind of samples are usually technically difficult because of the 
heterogeneity of the sample, abundant dead cells and auto fluorescence (Kuonen et al., 2010). In our 
samples, proportions of living cells among single cells were important (Figure 7), but bulk populations 
also contained numerous dead cells likely due to, among others, areas of necrosis, tumor dissociation 
and thawing steps. For these reasons, the first part of the gating procedure, consisting in dead cells 
removal and doublets discarding, was necessary to eliminate fragments and dead cells allowing us to 
reduce nonspecific signal in the following steps of phenotypic analysis. Moreover, to further reduce 
nonspecific staining due to non-specific binding of antibodies to cells, cells were incubated with a FcR 
receptor blocking reagent. Autofluorescence and unspecific signal could also explain in part the 




 Despite the fact that bulk populations contain numerous dead cells, the immune infiltrate is 
prominent (> 40%). It is composed mainly of cells with an MDSC-like phenotype, macrophages and 
subsets of T cells (T regs, double negative and double positive). Other cell types are associated with 
immune infiltrate and seem to play a role in cancer but little is known about their functions 
(monocytes, Th17). 
 To complete the characterization of these populations, it would be necessary to use different 
sets of antibodies to target cells more precisely. It would be interesting, to use fresh samples to study 
the function of characterized cells and examine whether macrophages display M1 or M2 properties. 
MDSC is a functional label. Therefore, it would be also necessary to characterize more in detail 
putative MDSCs associated with sarcomas, to isolate them and confirm their immunosuppressive 
function through culturing mixed populations of T cytotoxic cells and MDSCs and reporting the effect 
of the latter on the former over time. Functionality of T reg cells should be also investigated in 
further studies. 
Although it is impossible to extrapolate our results toward functionality, it is plausible that 
immune infiltrates characterized in this study may correspond to an immunosuppressive phenotype. 
Further work obviously needs to be done to conclude with any certainty the function of these 
populations. However, if they are immunosuppressive, there may be room for therapeutic 





1. D'Acquisto F & Crompton T (2011). CD3+CD4-CD8- (double negative) T cells: Saviours or 
vilains of the immune response? Biochem Pharmacol, 82(4):333-40. 
2. Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight SC et al. (2001). Increased 
production of immature myeloid cells in cancer patients: a mechanism of 
immunosuppression in cancer. J Immunol, 166(1):678-89. 
3. Chanmee T, Ontong P, Konno K, Itano N (2014). Tumor-associated macrophages as 
major players in the tumor microenvironment. Cancers (Basel), 6(3):1670-90. 
4. Coussens LM & Werb Z (2002). Inflammation and cancer. Nature, 420(6917):860-7. 
5. Danbara M, Yoshida M, Kanoh Y, Jiang SX, Masuda N, Akahoshi T, Higashihara M (2009). 
Flow cytometric detection of small cell lung cancer cells with aberrant CD45 expression 
in micrometastatic bone marrow. Jpn J Clin Oncol, 39(11):771-5. 
6. Danese S & Rutella S (2007). The Janus face of CD4+CD25+ regulatory T cells in cancer 
and autoimmunity. Curr Med Chem, 14(6):649-66. 
7. Davidoff AM (2012). Wilms tumor. Adv Pediatr, 59(1):247-67. 
8. De Leeuw RJ, Kost SE, Kakal JA, Nelson BH (2012). The prognostic value of FoxP3+ 
tumor-infiltrating lymphocytes in cancer: a critical review of literature. Clin Cancer Res, 
18(11):3022-9. 
9. Gabrilovitch DI & Nagaraj S (2009). Myeloid-derived suppressor cells as regulators of the 
immune system. Nat Rev Immunol, 9(3):162-74. 
10. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C et al. (2006). 
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict 
Clinical Outcome. Science, 313:1960-1964. 
11. Galon J, Angell HK, Bedognetti D and Marincola FM (2013). The continuum of cancer 
immunosurveillance: prognostic, predictive, and mechanistic signature. Immunity, 
39:11-26. 
12. Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, Kim D, Nair WS, Xu Y, Khuong A, 
Hoang CD, Diehn M, West RB, Plevritis SK & Alizadeh AA (2015). The prognostic 
landscape of genes and infiltrating immune cells across human cancers. Nature 
Medicine, 21(8):938-45. 
13. Hanahan D & Weinberg RA (2000). The hallmarks of cancer. Cell, 100(1):57-70. 




15. Hillhouse EE & Lesage S (2013). A comprehensive review of the phenotype and function 
of antigen-specific immunoregulatory double negative T cells. J Autoimmun, 40:58-65. 
16. Johann PD, Vaegler M, Gieseke F, Mang P, Armeanu-Ebinger S, Kluba T et al. (2010). 
Tumour stromal cells derived from paediatric malignancies display MSC-like properties 
and impair NK cell cytotoxicity. BMC Cancer, 10:501. 
17. Joyce JA & Pollard JW (2009). Microenvironmental regulation of metastasis. Nat Rev 
Cancer, 9(4):239-52. 
18. Kerouanton A, Jimenez I, Cellier C, Laurence V, Helfre S, Pannier Set al. (2014). Synovial 
sarcoma in children and adolescents. J Pediatr Hematol Oncol, 36(4):257-62. 
19. Kumar V, Abbas AK, Fausto N, Aster J. Robbins and Cotran Pathologic Basis of Disease, 
8th Edition, Elsevier, 2010. 
20. Kuonen F, Touvrey C, Laurent J, Ruegg C (2010). Fc block treatment, dead cells exclusion, 
and cell aggregates discrimination concur to prevent phenotypical artifacts in the 
analysis of subpopulations of tumor-infiltrating CD11b+ myelomonocytic cells. 
Cytometry Part A, 77A:1082-90. 
21. Martinez FO & Gordon S (2014). The M1 and M2 paradigm of macrophage activation: 
time for reassessment. F1000Prime Rep, 6:13. 
22. Mirza N, Fishman M, Fricke I, Dunn M, Neuger AM, Frost TJ et al. (2006). All-trans-
retinoic acid improves differentiation of myeloid cells and immune response in cancer 
patients. Cancer Res, 66(18):9299-307. 
23. Moretta L, Montaldo E, Vacca P, Del Zotto G, Moretta F, Merli P et al. (2014). Human 
Natural Killer Cells: Origin, Receptors, Function, and Clinical Applications. Int Arch Allergy 
Immunol, 164:253-264. 
24. Prendergast GC & Jaffee EM. Cancer Immunotherapy: Immune Suppression and Tumor 
Growth. 2nd Edition, Academic Press, Elsevier, 2013. 
25. Riggi N & Stamenkovic I (2007a). The biology of Ewing sarcoma. Cancer Let, 254(1):1-10. 
26. Riggi N, Cironi L, Suva ML, Stamenkovic I (2007b). Sarcomas: genetics, signaling, and 
cellular origins. Part 1: The fellowship of TET. J Pathol, 213(1):4-20. 
27. Ruffell B, Affara NI, Coussens LM (2012). Differential macrophage programming in the 
tumor microenvironment. Trends Immunol, 33(3):119-26. 
28. Schmielau J & Finn OJ (2001). Activated granulocytes and granulocyte-derived hydrogen 
peroxide are the underlying mechanism of suppression of T-cell function in advanced 
cancer patients. Cancer Res, 61(12):4756-60. 
29. Smith SC, Poznanski AA, Fullen DR, Ma L, McHugh JB, Lucas DR et al. (2013). CD34-




30. Solito S, Marigo I, Pinton L, Damuzzo V, Mandruzzato S, Bronte V (2014). Myeloid-
derived suppressor cell heterogeneity in human cancers. Ann N Y Acad Sci, 1319:47-65. 
31. Sorbye SW, Kilvaer T, Valkov A, Donnem T, Smeland E, Al-Shibli K, et al. (2011). 
Prognostic impact of lymphocytes in soft tissue sarcomas. PLoS One, 6(1):e14611.  
32. Sorbye SW, Kilvaer TK, Valkov A, Donnem T, Smeland E, Al-Shibli K et al. (2012). 
Prognostic impact of peritumoral lymphocyte infiltration in soft tissue sarcomas. BMC 
Clin Pathol, 12:5. 
33. Strachan DC, Ruffell B, Oei Y, Bissell MJ, Coussens LM, Pryer N and Daniel D. (2013). 
CSF1R inhibition delays cervical and mammary tumor growth in murine models by 
attenuationg the turnover of tumor-associated macrophages and enhancing infiltration 
by CD8+ T cells. Oncoimmunology, 2:12, e26968. 
34. Suva ML, Cironi L, Riggi N, Stamenkovic I (2007). Sarcomas, genetics, signaling, and 
cellular origins. Part 2: TET-independent fusion proteins and receptor tyrosine kinase 
mutations. J Pathol, 2013(2):117-30. 
35. Thomson CW, Lee B, Zhang L (2006). Double-negative regulatory T cells: non-
conventional regulators. Immunol Res, 34(1-2):163-78. 
36. de Visser KE, Eichten A, Coussens LM (2006). Paradoxical roles of the immune system 
during cancer development. Nat Rev Cancer, 6(1):24-37. 
37. Weinberg RA. The Biology of Cancer. 2nd Edition, Garland Science, 2013. 
38. Wogan GN, Hecht SS, Feltron JS, Conney AH, Loeb LA (2004). Environmental and 
chemical carcinogenesis. Semin Cancer Biol, 14(6):473-86. 
39. Young KJ, Kay LS, Philips MJ, Zhang Li (2003). Antitumor activity mediated by double-
negative T cells. Cancer Res, 63(22):8014-21. 
40. Young MR, Petruzzelli GJ, Kolesiak K, Achille N, Lathers DM, Gabrilovich DI (2001). 
Human squamous cell carcinomas of the head and neck chemoattract immune 
suppressive CD34(+) progenitor cells. Hum Immunol, 62(4):332-41. 
41. Zea AH, Rodriguez PC, Atkins MB, Hernandez C, Signoretti S, Zabaleta J et al. (2005). 
Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a 
mechanism of tumor evasion. Cancer Res, 65(8):3044-8. 
 
